What's new

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Mar 17, 2025 - 14:46
 0
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024
Read More

Tags:

Previous Article

BMW: 2025 margins to remain below target

Next Article

Go Outdoors rolls out body cameras to 25 stores

Related Posts

Human medicines European public assessment report (EPAR): Avamys, fluticasone furoate, Date of authorisation: 11/01/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

Herbal medicinal product: Prunus avium peduncleArray,Array, D: Draft under discussion

Herbal medicinal product: Prunus avium peduncleArray,Ar...

Feb 25, 2025  0

Human medicines European public assessment report (EPAR): MicardisPlus, Date of authorisation: 19/04/2002, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 26, 2025  0